Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics, Inc. (NASDAQ:TXG) ... The company had successful launches of its Visium instrument in late 2022 and its new Xenium platform in early 2023. In addition, ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Visium HD 3′ for high resolution, species-agnostic spatial profiling: 10x Genomics unveiled its plans to bring its flagship Visium v1 3′ assay, launched in 2019, into high resolution with ...

PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium ...

PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that ...

PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that ...

French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to ...

Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., ...